2. Why is the FDA approval and the scientific research not adjusted to achieve faster results and approvals ? The system needs to take into account the risks that an individual already faces from ineffective treatments. We should not have delays that do not result in actual increases in safety.

3. We need to focus medical research guided by metrics for results in extending lifespan and improved health. There is too much money going into treatments that are not improving lifespan but which replace a marginal effective but profitable drug for treating some symptom. Too much just flows to institutions that have historically received money but which are not measured by the results that they have delivered.

4. There is also the budget tension between hospices and costs for those who are sick and research to actually cure aging and disease. The bulk of the money for medical research should be focused on impacting aging processes and resistance and recuperation from disease. The allocation should be made at the top level. Budget $X for underlying causes of aging and interventions, C$ for disease cures, Y$ for symptom management and Z$ for hospice care. The X$ amount is far too small and often gets diverted into the other buckets.